Meridian Bioscience Expands Production Capacity with Support from NIH, JobsOhio, and the Village of Newtown
February 03, 2021 10:30 ET | Source: Meridian Bioscience Inc. Meridian Bioscience Inc. Cincinnati, Ohio, UNITED STATES
CINCINNATI, Feb. 03, 2021 (GLOBE NEWSWIRE) Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today announced that it will increase production capacity of the company s SARS-CoV-2 molecular diagnostic test on its Revogene
® platform after receiving a $5.5M award from the National Institute of Health (NIH) Rapid Acceleration of Diagnostics (RADx
SM) initiative and an additional grant from JobsOhio.
The funding will help Meridian expand production of Revogene
Share this article
Share this article
BETHESDA, Maryland., Dec. 28, 2020 /PRNewswire-HISPANIC PR WIRE/ The National Institutes of Health has awarded eight research grants to develop approaches for identifying children at high risk for Multisystem Inflammatory Syndrome in Children (MIS-C), a rare and severe after-effect of COVID-19 or exposure to the virus that causes it. Up to $20 million will be provided for the projects over four years, pending the availability of funds. These awards underscore NIH s commitment to identifying children at risk for MIS-C, which will inform development of interventions to improve their health outcomes, said Diana Bianchi, M.D., director of NIH s
NIH to support radical approaches to nationwide COVID-19 testing and surveillance
RADx-rad program will fund non-traditional and repurposed technologies to combat the current pandemic and address future viral disease outbreaks.
The National Institutes of Health has awarded over $107 million to support new, non-traditional approaches and reimagined uses of existing tools to address gaps in COVID-19 testing and surveillance. The program also will develop platforms that can be deployed in future outbreaks of COVID-19 and other infectious diseases. A part of the Rapid Acceleration of Diagnostics (RADx) initiative, the awards from the RADx Radical (RADx-rad) program will support 49 research projects and grant supplements at 43 institutions across the United States. It will focus on non-traditional viral screening approaches, such as biological or physiological markers, new analytical platforms with novel chemistries or engineering, rapid detection strategies, point-of-care devices,
Awards part of a larger effort to study pediatric COVID-19 and related conditions.
The National Institutes of Health has awarded eight research grants to develop approaches for identifying children at high risk for Multisystem Inflammatory Syndrome in Children (MIS-C), a rare and severe after-effect of COVID-19 or exposure to the virus that causes it. Up to $20 million will be provided for the projects over four years, pending the availability of funds.
“These awards underscore NIH’s commitment to identifying children at risk for MIS-C, which will inform development of interventions to improve their health outcomes,” said Diana Bianchi, M.D., director of NIH’s